Product Quest Announces Acquisition Initiative

Product Quest Announces Acquisition Initiative

Daytona Beach, Florida, November 18, 2015 – Product Quest Manufacturing (the "Company"), a manufacturer of over-the-counter and pharmaceutical topical products, announced today that it is actively seeking acquisitions.

John Regan, Chief Executive Officer of Product Quest, said, "We are well-capitalized through our partnership with Kainos Capital and actively seeking to pursue strategic acquisitions to grow our platform."

Product Quest manufactures topical liquids, creams, gels and sprays for branded and retail customers. Products manufactured by the Company include sun blocks, moisturizers, first aid products, acne treatments and animal medications, with new product development supported by a robust R&D team.

Attractive acquisition targets include:

·         Over-the-counter brands in health care categories including sun, anti-aging, skin, acne, first aid, foot, ear and eye, cough and cold remedies and laxatives

·         Manufacturers of over-the-counter topical products, including aerosols, sterile products, creams, lotions and continuous sprays

·         Manufacturers of ingestible products including liquids, lozenges, soft gels, tablets and capsules

·         Generic drugs or Abbreviated New Drug Applications ("ANDAs")

"We are seeking acquisitions up to $150 million in revenue. We are also interested in ANDAs with strong commercial potential but no current revenue," says Regan.

Product Quest is seeking acquisitions throughout North America, and is capable of integrating businesses with existing management teams, as well as brand and asset carve-outs.

For more information regarding Product Quest and its acquisition criteria, please contact Bill Jennings at[email protected].

 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.